Related Experiment Video

Updated: Jun 11, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol

George L Bakris1, Jan N Basile, Thomas D Giles

  • 1Hypertensive Diseases Unit, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA.

The American Journal of Medicine
|July 9, 2010
PubMed

Insights

Conventional beta-blockers may offer poorer outcomes and quality of life. Vasodilating beta-blockers, like nebivolol, present distinct advantages for complex hypertension cases, including patients with diabetes or the cardiometabolic syndrome.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Beta-blockers are guideline-recommended for hypertension, especially with high cardiovascular disease (CVD) risk.
  • Concerns exist regarding conventional beta-blockers' clinical outcomes, quality of life, and metabolic effects.
  • Beta-blockers are a diverse class, including nonvasodilating and vasodilating agents.

Purpose of the Study:

  • To review pharmacologic, mechanistic, and hemodynamic differences between conventional and vasodilating beta-blockers.
  • To highlight the cardioselective vasodilating beta-blocker nebivolol.
  • To explore clinical implications for complicated hypertension management.

Main Methods:

  • Review of existing literature on beta-blocker pharmacology and clinical outcomes.
  • Comparative analysis of vasodilating versus nonvasodilating beta-blockers.
  • Focus on nebivolol's properties and potential benefits.

Main Results:

  • Vasodilating beta-blockers, particularly nebivolol, exhibit different properties compared to conventional agents.
  • These differences may lead to improved clinical outcomes in specific patient populations.
  • Mechanism of action is a crucial factor in beta-blocker selection.

Conclusions:

  • Vasodilating beta-blockers offer potential advantages over conventional agents.
  • Nebivolol is a promising option for complicated hypertension, including in patients with diabetes, cardiometabolic syndrome, the elderly, and African Americans.
  • Tailoring beta-blocker choice based on mechanism of action is clinically significant.

More Related Videos

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells08:32

Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells

Published on: March 16, 2017

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...